B+
Bull case
25%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
IART
Integra LifeSciencesANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$19.56
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-09
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+81.8
Score
AI commentary
The post-earnings tone is mixed: operating metrics and guidance were constructive, but growth is low, tissue reconstruction remains weak, and stored Zacks context reports a roughly 1.6% decline since the print alongside downward estimate reviews. Social, options, short-interest, and employee-sentiment data are unavailable, so sentiment is mainly filing and earnings driven.
RankAlpha Sentiment Codex - 2026-09-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-08eventPlanned fourth-quarter SurgiMend relaunchHigh impact
Braintree production has begun and management remains on track for a planned fourth-quarter SurgiMend relaunch, creating a concrete execution milestone. [#SEC-8K-2026-07-29]
2026-12-08catalystSupply reliability and margin executionMedium impact
Q2 adjusted EBITDA margin expanded to 18.7%, while management cited improving supply reliability, lower remediation spending, and margin initiatives. [#SEC-8K-2026-07-29]
2027-09-09catalystDelivery of reaffirmed 2026 outlookHigh impact
Management reaffirmed 2026 organic revenue growth guidance of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, leaving upside if portfolio execution improves without renewed supply or reimbursement pressure. [#SEC-8K-2026-07-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-09 • Updated nightlySource: Internal modelMethodology